All Brands Owned by Cencora Inc.

What does Cencora do?
Cencora distributes pharmaceutical products, including brand name drugs, generic drugs, specialty medications, and over the counter healthcare products, to pharmacies, hospitals, physician offices, and other healthcare providers across the United States and internationally. The company also provides manufacturer services, patient support programs, specialty logistics, veterinary pharmaceutical distribution, and physician practice management through its subsidiaries. In fiscal 2025, the company generated $321.3 billion in revenue.

Is Cencora publicly traded?
Yes, Cencora, Inc. trades on the New York Stock Exchange under ticker symbol COR. The company was previously listed under the ticker ABC as AmerisourceBergen and changed to COR on August 30, 2023, when the rebranding to Cencora was completed. The company has no controlling shareholder, though Walgreens Boots Alliance holds a significant stake as the largest single investor.

What is Cencora's annual revenue?
In fiscal year 2025 (ended September 30, 2025), Cencora reported revenue of $321.3 billion, a 9.3% increase from $294.0 billion in fiscal 2024. The company is one of the largest companies in the United States by revenue, consistently ranking in the top 20 of the Fortune 500. Adjusted diluted EPS was $16.00, up 16.3% from $13.76 in the prior year.

Why did AmerisourceBergen change its name to Cencora?
AmerisourceBergen changed its name to Cencora on August 30, 2023, to reflect its evolution from a primarily domestic pharmaceutical distributor into a global healthcare solutions organization. The rebranding followed the 2021 acquisition of Alliance Healthcare from Walgreens Boots Alliance for approximately $6.5 billion, which significantly expanded the company's international operations. The new name was selected from hundreds of possibilities and was inspired by the company's team members and customers around the world. The ticker symbol changed from ABC to COR on the same date.

Who is Cencora's CEO?
Robert P. Mauch became President and CEO of Cencora on October 1, 2024, succeeding Steven H. Collis, who had served as CEO since 2011. Collis transitioned to the role of Executive Chairman. Mauch previously served as Chief Operating Officer of the company.

What is Cencora's role in the opioid settlement?
Cencora (then AmerisourceBergen), along with McKesson and Cardinal Health, reached a $21 billion settlement with U.S. states and local governments in February 2022 to resolve claims that the three distributors failed to adequately monitor suspicious opioid orders. Cencora's share of the settlement is approximately $6.1 billion, representing its 31% portion, to be paid over 18 years. A minimum of 85% of the settlement payments must be used for addiction treatment and prevention services. The distributors did not admit liability or wrongdoing. A separate settlement with Johnson & Johnson brought the total to approximately $26 billion.

What is the RCA acquisition?
In January 2025, Cencora completed the acquisition of Retina Consultants of America (RCA), a leading management services organization of retina specialists, from Webster Equity Partners. Cencora acquired approximately 85% interest in RCA for a cash outlay of $4.4 billion, with RCA physicians and management retaining a 15% minority interest. The acquisition added nearly 300 retina specialists to Cencora's portfolio and expanded its physician management services capabilities within the U.S. Healthcare Solutions segment.